Last reviewed · How we verify
Carvedilol IR 25mg, QD
Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.
Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload. Used for Heart failure with reduced ejection fraction, Hypertension, Angina pectoris.
At a glance
| Generic name | Carvedilol IR 25mg, QD |
|---|---|
| Also known as | Dilatrend IR |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | Beta-blocker with alpha-1 antagonist activity |
| Target | Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Carvedilol blocks beta-1, beta-2, and alpha-1 adrenergic receptors, reducing sympathetic nervous system activity on the heart and blood vessels. This dual action decreases heart rate and contractility while causing vasodilation, leading to reduced blood pressure and improved cardiac efficiency. It is commonly used in heart failure and hypertension management.
Approved indications
- Heart failure with reduced ejection fraction
- Hypertension
- Angina pectoris
- Post-myocardial infarction
Common side effects
- Dizziness
- Fatigue
- Hypotension
- Bradycardia
- Hyperglycemia
- Erectile dysfunction
Key clinical trials
- Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carvedilol IR 25mg, QD CI brief — competitive landscape report
- Carvedilol IR 25mg, QD updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI